TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Trading Up 3.7 %

Shares of NASDAQ TLSI opened at $5.29 on Thursday. The company has a market capitalization of $161.31 million, a P/E ratio of -2.12 and a beta of 0.48. The stock has a 50 day moving average of $5.31 and a 200-day moving average of $4.71. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TLSI shares. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target for the company. Lake Street Capital started coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.56.

Insider Activity at TriSalus Life Sciences

In other news, CEO Mary T. Szela purchased 4,826 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.42 per share, with a total value of $26,156.92. Following the purchase, the chief executive officer now owns 429,503 shares in the company, valued at $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sean Murphy purchased 15,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were purchased at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the purchase, the insider now owns 182,732 shares in the company, valued at $970,306.92. This trade represents a 8.94 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 54,856 shares of company stock worth $294,608 in the last 90 days. Corporate insiders own 32.80% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.